Temple 8 Research
AI Buildout, Macro & Energy Infrastructure Research
Consumer staples are a lose-lose here because they are already overvalued at 26x forward earnings versus a 22.7x five-year average, the highest since just before the tech bubble burst. With stocks this richly valued, there is little left to rotate into if the economy weakens next year, and the healthcare rotation is well under way. If the economy holds, high rates hurt staples; if it weakens, they are too expensive to hold up even with rate cuts, except perhaps Campbell's. x.com x.com
Rising freight and oil costs threaten consumer staples margins, with plastic a significant input, while a weakening consumer adds trade-down risk. That makes chasing the recent bid for staples unattractive. x.com
Hyperscaler credit stress and weak financials-versus-staples leadership warn of downside risk in the S&P 500 consolidation. Spreads have broken July wides, though an upside breakout is probable if financials stabilize. So far, tech weakness has lowered yields as Fed hikes are priced out, letting defensives rally and the S&P chop. If the Fed signals Nasdaq weakness won't stop tightening without better data, the tech-yield link could break in an uncomfortable, 2018-like direction. x.com x.com … Show more
US consumer staples look good here as a safe-haven play. x.com
Campbell's outlook is deteriorating. It cut its dividend from 39 cents to 25 cents, lowered guidance and said 2027 looks even worse. x.com
Campbell's earnings estimates are in an absolutely brutal death march. x.com
Consumer staples such as Costco, Walmart, Procter & Gamble, Kroger, General Mills, Coca-Cola and PepsiCo are among the names to study if hantavirus fear dominates the next 60-90 days, whether or not a lockdown happens. Markets react to perception before confirmed reality, and fear alone shifts attention, behavior and capital flows. A real pandemic is not needed; the fear narrative only has to persist long enough for capital and behavior to start shifting. x.com
US large-cap equities likely have more downside, because consumer staples leading alongside small-cap biotech signals a reason to be wary. It is rare for both to lead at once, with small-cap biotech up 24.44% this year and 82.86% over the past year. July has historically been the S&P 500's best month since 1928, averaging about 1.7% and rising roughly 60% of the time, but seasonality is not a reliable guide here. x.com x.com x.com
Consumer staples should strongly outperform in 2026, one of the year's expected surprises, if the AI bubble bursts. In that scenario circular financing deals unwind, AI capex slows abruptly on return-on-investment worries and power bottlenecks, and depreciation and weaker demand wreck AI earnings estimates. PepsiCo, Coca-Cola, Procter & Gamble and Kimberly-Clark would then materially outperform the Magnificent 7, with PepsiCo beating most staples on better organic unit growth. x.com
US large-cap stocks are frothy and now need years of earnings to validate today's prices, even though the rally is not irrational. Per FactSet, S&P 500 earnings are up about 28% versus 13% expected, but the Shiller P/E is near 42, close to 1999-2001 extremes. Per @KobeissiLetter, leveraged ETF assets hit a record $177B and the leading-to-coincident indicator ratio of 0.84 matches the 2008 low; per @charliebilello, 90+ day delinquencies hit 13.1% for credit cards and 5.6% for auto loans. x.com … Show more
US large-cap equities look stretched as the S&P 500's 4.7% earnings yield sits below the 5.2% Treasury yield, the first extended stretch since 1999-2000. 2026 EPS estimates imply 32% growth and a 21.2x P/E. The 10-year yield hit 5.28%, its highest since 2007, which pressures long-duration, high-P/E stocks most. Since recent inflation is mostly an oil supply shock, yields could fall once the war with Iran ends and Brent eases. x.com x.com
